Frank Gillardon
Boehringer-Ingelheim Pharma GmbH & Co. KG
CNS Research
Birkendorfer St. 65
88397 Biberach an der Riss
Germany
[email]@bc.boehringer-ingelheim.com
Name/email consistency: high
- Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro. Gillardon, F. Neuroscience (2009)
- Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? Gillardon, F. J. Neurochem. (2009)
- The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity. Gillardon, F., Kloss, A., Berg, M., Neumann, M., Mechtler, K., Hengerer, B., Dahlmann, B. J. Neurochem. (2007)
- Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Gillardon, F., Rist, W., Kussmaul, L., Vogel, J., Berg, M., Danzer, K., Kraut, N., Hengerer, B. Proteomics (2007)
- Differential mitochondrial protein expression profiling in neurodegenerative diseases. Gillardon, F. Electrophoresis (2006)
- Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor. Gillardon, F., Steinlein, P., Bürger, E., Hildebrandt, T., Gerner, C. Proteomics (2005)
- Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis. Gillardon, F., Schrattenholz, A., Sommer, B. J. Cell. Biochem. (2005)